SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders watching guidance, subscriber engagement and advertising growth amid concerns about slowing growth, content quality and competition; recent leadership changes and layoffs add to the debate. Bulls see pessimism as overdone, while bears expect further weakness, leaving sentiment sharply divided ahead of the report.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp rebound on elevated volume has traders speculating about a news leak or buyout, partly reading CEO Angelos Stergious anniversary message as a signal; neither claim is confirmed. The main underlying focus is the Phase 3 REGAL trials final analysis, triggered at 80 deaths after 78 were last disclosed: bulls interpret the wait as a possible sign of longer survival, while skeptics note the results remain uncertain.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is largely tied to anticipation of the detailed Phase 3 melanoma cancer-vaccine results with Merck at ESMO, after positive topline results sparked a major revaluation. Traders are split between momentum-driven optimism about the broader oncology platform and concerns that expectations and valuation are stretched, with some anticipating a sell-the-news pullback.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp move is drawing attention as shares push above recent technical resistance, while traders point to anticipated DM1 and FSHD siRNA data as potential catalysts. Some see strength or possible short covering, while others caution that past rallies have faded and no new catalyst is confirmed in the discussion.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure amid broader concerns about neocloud funding, debt, and whether AI infrastructure spending will generate adequate returns; co-CEO Daniel Roberts comments that the data centers were cash-funded and customer prepayments help cover GPU costs are being cited as reassurance. Traders are split between viewing the selloff as an oversold buying opportunity and expecting further downside, with many frustrated that IREN has lagged peers.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.

Cardano

ADAs weak, range-bound trading and exposure to broader crypto-market selling dominate the discussion, with many traders frustrated by failed rallies and warning of more downside. Others view the pullback as consolidation and say they are accumulating or holding, while watching technical resistance and Bitcoins direction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM shares are under pressure after a quarterly earnings beat failed to offset a narrowed full-year profit outlook that left the midpoint unchanged; weaker U.S. sales and market share also weighed on the reaction. Traders are split between viewing the selloff as overdone given stronger cash-flow guidance and a new buyback, and focusing on the lack of a higher profit outlook.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs earnings beat and raised outlook have been met with a sharp selloff, prompting frustration and debate over why strong demand and guidance have not supported the shares. Traders point to profit-taking and elevated expectations, while cost pressures, weaker cash conversion and an insurance-unit loss have raised questions about margins and the quality of the results.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, driving attention alongside analyst upgrades. Traders are divided over the modest placebo-adjusted symptom improvement and concerns about discontinuations and agitation, with some viewing the data as a positive proof of concept and others arguing the rally may fade.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp has driven the sharp share move, with traders viewing the cash sale as a balance-sheet and strategic reset. The community is split between bullish momentum and concern that divesting a revenue-generating unit could leave the remaining business smaller and debt pressures unresolved.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bionano Genomics Stock Surges Tuesday: What's Going On?

Bionano Genomics is surging Tuesday as investors weigh its growth strategy and favorable milestones for its genome mapping technology.read more...

Bionano Genomics (BNGO) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Bionano Genomics (BNGO) Upgraded to Buy: What Does It Mean for the Stock?

Bionano Genomics (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Why Fast-paced Mover Bionano Genomics (BNGO) Is a Great Choice for Value Investors

Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates

Bionano Genomics (BNGO) delivered earnings and revenue surprises of +6.17% and +2.88%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates

Arvinas (ARVN) delivered earnings and revenue surprises of +5.01% and -0.74%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1

Lexicon (LXRX) delivered earnings and revenue surprises of +100.00% and +141.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Bionano Genomics (BNGO) Earnings Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

Bionano Genomics Stock Soars As Efficiency Gains Meet Growth Story

Bionano Genomics stock soared on Monday as investors anticipated the company's Q4 earnings report.read more...

United Airlines, AGI And 3 Stocks To Watch Heading Into Monday

US stock futures down, Caledonia Mining, United Airlines & Agi to report earnings, Cheetah Net & BioNano Genomics to release results.read more...

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Bionano Genomics Inc

Bionano Genomics Retail Mood Turns ‘Extremely Bearish’ Amid Revenue Guidance Shortfall

Equity

Bullish Sentiment

Bionano Genomics triggered&nbsp;heavy retail chatter on Wednesday after the company provided a full-year 2025 revenue forecast in the range of $26 million to $30 million, falling short of the consensus estimate of $30.33 million.The company's second-quarter (Q2) revenue projection fell between $6.3 million and $6.8 million, while analysts expected $7.01 million.Bionano disclosed $6.5 million in revenue for Q1 2025, which surpassed the consensus figure of $6.25 million.&nbsp;The gross margin percentage increased to 46% compared to 32% from the previous year.&nbsp;GAAP operating expenses plunged by 66% to $11.4 million, while non-GAAP costs reduced by 65% to $8.5 million because of downsizing and restructuring product development efforts.Bionano shares closed 5.3% lower at $3.74 on Tuesday but rebounded 20.3% to $4.50 in after-hours trading.CEO Erik Holmlin noted that the March quarter represented the first period for executing their new strategy, which targets routine users of OGM systems and VIA software.&nbsp;The company reported stable utilization rates and increased consumables sales to routine users, which led to an extended cash runway until the first quarter of 2026.Bionano's Q1 sales of nanochannel array flowcells reached 6,994 units, representing a 15% decrease from the previous year, although existing customer sales expanded by 1% when accounting for new account volumes.&nbsp;The company added nine OGM systems to its network in the quarter, which increased its total system count to 379 from 347 at the same time last year.Bionano confirmed its plans to deploy between 15 and 20 new OGM systems in 2025.On Stocktwits, retail sentiment was ‘extremely bearish’ amid a&nbsp;6,300% surge in 24-hour message volume.One user warned of a potential 35% drop in the stock, while another described the company as obsolete and predicted a decline toward zero.<stembedurl>https://stocktwits.com/Jewkee/message/614685155</stembedurl><stembedurl>https://stocktwits.com/v92/message/614672774</stembedurl>The stock has declined 75.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Bionano Genomics (NASDAQ: BNGO) logo seen displayed on a smartphone with an Artificial intelligence (AI) chip and symbol in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Despite a 46% gross margin improvement and significant cost cuts, the stock fell over 5% on Wednesday before jumping 20% in after-hours trading

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$1.27
Prev Close	$1.22
Open	$1.21
Dividend Yield	0.00%
50-Day Moving Average	$1.37
Beta	1.51
Avg. Volume	2.51M
PE Ratio	-0.33

52-Week High	$2.23
52-Week Low	$1.00
Market Capitalization	$14.37M
EPS (Annual)	-$4.85
Price to Book	0.45
Revenue Per Employee	$293,896.91

Feed

News

Sentiment

Earnings

Fundamentals

Info

BNGO Fundamentals